Phase III study of efpeglenatide in combination with basal insulin for treatment of type 2 diabetes

Trial Profile

Phase III study of efpeglenatide in combination with basal insulin for treatment of type 2 diabetes

Planning
Phase of Trial: Phase III

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Efpeglenatide (Primary) ; Insulin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Feb 2018 New trial record
    • 08 Feb 2018 According to a Sanofi media release, the company plans two new phase III studies in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top